

DiagnaMed Launches “Health GenAI”, a New Division for Generative AI Healthcare Solutions

Focused on Health GenAI and CERVAI™, a generative AI brain health platform

TORONTO, May 10, 2023 --DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is pleased to announce the launch of Health GenAI, a new division focused on the development and commercialization of a suite of generative AI ready-made and customizable applications powered by GPT-4 to support the healthcare market in improving patient outcomes, operational workflow and efficiency. The Company expects to launch at least three products from its Health GenAI division this year.

DiagnaMed is organized to focus on its two divisions, CERVAI™, a generative AI brain health platform, and Health GenAI. According to Market.us, generative AI in the healthcare market is set to reach approximately USD 17 billion by 2032, driven by the adoption of automation by healthcare operators in drug discovery and development, medical imaging and diagnostics, personalized medical interventions, and hospitals and clinical decision support systems.

Fabio Chianelli, Chairman of DiagnaMed, commented: "We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI™, our generative AI brain health platform."

As part of its Health GenAI division, the Company recently announced the launch of its first commercial product, FormGPT.io (www.FormGPT.io), a generative AI data collection and analysis solution for the healthcare market, which was born from the development experience and features of CERVAI™. FormGPT.io allows licensed medical professionals, hospitals, and life science to create customized forms and surveys with the support of ChatGPT and collect relevant patient data, obtain pre-and-post-visit and treatment feedback, monitor patient progress, and analyze results for decision-making. FormGPT.io empowers licensed professionals and clinical researchers to easily and quickly develop forms and surveys that complement their workflow and specific patient and research objectives. In addition, FormGPT.io aims to improve user services, workflow, patient outcomes and engagement. The Company is making its minimal viable product version of FormGPT.io available to the public with a 7-day free trial.

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a generative AI healthcare solutions company, is focused on the development and commercialization of CERVAI™, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI SaaS products for the healthcare market. Learn more at DiagnaMed.com.

For more information about DiagnaMed, please contact:

Fabio Chianelli
Chairman of the Board
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accepted responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in DiagnaMed's final prospectus dated October 26, 2022, which is available on the Company's profile at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.